Telogen Effluvium in Patients Recovering from COVID-19

    September 2021 in “ Skin
    Nancy Wei, Emily Elbogen, Joshua Dan, Anna Chessky, Ryan Rivera-Oyola, Mark Lebwohl
    Image
    Studysummary In this observational study, nine out of ten patients developed Telogen Effluvium after mild COVID-19 symptoms, with hair shedding starting on average 73 days following infection.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →